阿可替尼联合来那度胺及利妥昔单抗或奥妥珠单抗的MRD驱动初治套细胞淋巴瘤治疗
这项2期研究评估阿可替尼联合来那度胺加利妥昔单抗(ALR)或奥妥珠单抗(ALO)联合纵向MRD监测初治套细胞淋巴瘤的疗效与安全性。主要终点为12周期诱导后分子完全缓解。ALR组总缓解率100%、完全缓解率83%、分子完全缓解率67%;ALO组总缓解率、完全缓解率和分子完全缓解率均为90%。
要点
- ALR组12周期诱导后总缓解率100%、完全缓解率83%、分子完全缓解率67%,最佳分子完全缓解率83%。
- ALR组中位随访53个月,4年总生存率91%、无进展生存率76%;TP53突变与无进展生存期不良相关(P=0.026)。
- ALO组诱导后总缓解率、完全缓解率和分子完全缓解率均为90%,2年总生存率和无进展生存率均为100%。
核心结论
- 该方案安全且有效,可作为套细胞淋巴瘤限时初始治疗,并需在反应适应策略中进一步评估。
研究设计与样本
- 2期研究,评估阿可替尼联合来那度胺加利妥昔单抗(ALR)或奥妥珠单抗(ALO)联合纵向微小残留病监测用于初治套细胞淋巴瘤。
- 主要目标为12周期诱导后分子完全缓解,定义为Lugano标准完全缓解且clonoSEQ检测微小残留病不可测(<10^-6)。
- 次要目标包括安全性、缓解和生存;探索性目标包括肿瘤突变谱和癌症个体化深度测序分析游离DNA。
- 达到uMRD6分子完全缓解的患者可在24周期后停用阿可替尼联合来那度胺;所有患者至少接受36周期抗CD20抗体治疗。
主要发现
- ALR组3/4级血液学毒性包括中性粒细胞减少(38%)、血小板减少(4%)和贫血(4%)。
- ALR组非血液学毒性包括皮疹(42%)、疲乏(4%)、恶心(4%)和呕吐(4%)。
- ALR组12周期诱导后总缓解率100%、完全缓解率83%、分子完全缓解率67%,最佳分子完全缓解率83%。
- ALR组中位随访53个月(范围46-60),4年总生存率91%、无进展生存率76%;TP53突变与无进展生存期不良相关(P=0.026)。
- ALO组诱导后总缓解率、完全缓解率和分子完全缓解率均为90%,2年总生存率和无进展生存率均为100%。
局限性
- 原文结论指出该方案需在反应适应策略中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 2 study evaluated the efficacy and safety of combining acalabrutinib and lenalidomide with either rituximab (ALR) or obinutuzumab (ALO), with longitudinal minimal residual disease (MRD) monitoring in frontline MCL treatment. The primary objective was molecular complete response (CR) after 12 cycles of induction, defined by Lugano criteria, and undetectable MRD of <10-6 (uMRD6) by clonoSEQ. Secondary objectives included safety, responses, and survival. Exploratory objectives included tumor mutation profiles and cell-free DNA (cfDNA) by cancer personalized profiling by deep sequencing. Patients in uMRD6 molecular CR were eligible for discontinuation of acalabrutinib plus lenalidomide after 24 cycles; all patients received a minimum of 36 cycles of anti-CD20 antibody treatment. In the ALR cohort, grade 3/4 hematologic toxicities included neutropenia (38%), thrombocytopenia (4%), and anemia (4%). Nonhematologic toxicities included rash (42%), fatigue (4%), nausea (4%), and vomiting (4%). The overall response rate (ORR) was 100%, CR rate was 83%, and molecular CR rate was 67% after 12 cycles of induction, with best molecular CR at 83%. At a median follow-up of 53 months (range, 46-60), the 4-year overall survival (OS) and progression-free survival (PFS) for ALR were 91% and 76%, respectively. TP53 mutations were adversely associated with PFS (P = .026). For ALO, ORR, CR, and molecular CR were 90% after induction, and 2-year OS and PFS were both at 100%. Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for patients with MCL and warrants further evaluation in response-adapted strategy. This trial was registered at www.ClinicalTrials.gov as NCT03863184.
引用
- Ruan J, Bond DA, Shah B, et al. MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood Adv. 2026. PMID: 41289154. doi:10.1182/bloodadvances.2025017760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。